Skip to content

Deep rTMS in Parkinson Disease Pain Syndromes

Deep rTMS in Parkinson Disease Pain Syndromes

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03504748
Enrollment
30
Registered
2018-04-20
Start date
2015-07-20
Completion date
2018-12-31
Last updated
2018-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Parkinson Disease

Keywords

deep repetitive transcranial magnetic stimulation, chronic pain, parkinson, treatment, non-motor symptom

Brief summary

Pain is the most prevalent non-motor symptom in Parkinson disease, and the motor improvement not always is related to the pain improvement with the medication treatment. By this, we are testing a non-invasive method called transcranial magnetic stimulation as an alternative to treat pain related to Parkinson disease. This technique can lead to either inhibitory or excitatory effects in brain circuits depending on stimulation parameters, and is known to provide analgesic effects.

Interventions

DEVICEdeep rTMS
DEVICEplacebo deep rTMS

Sponsors

University of Sao Paulo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Parkinson disease * Signed term of informed consent * Parkinsson disease related pain

Exclusion criteria

* Trauma of Skull, epilepsy don't treated * Use of medications decrease the seizure threshold * Patients in use of drugs, how cocaine and alcohol * neurosurgical clips, pacemakers, increased intracranial pressure (risk of sequelae after seizure) * Pregnant or lacting women * Moderate or severe cognitive impairment

Design outcomes

Primary

MeasureTime frameDescription
Change in baseline of Painbase line (moment of inclusion), day 15th, day 45th and in the last day of the sessions of rTMS (4X in two months)assessing by Visual Analog Scale for Pain (VAS). This scale range from 0 (no pain) to 10 (maximum pain), being considered an effective improvement in the patient's pain when the pain decreases at least in 30% from the basal score.

Countries

Brazil

Contacts

Primary ContactDaniel MD Ciampi, Phd
ciampi@usp.br+ 55 11 997753538
Backup ContactVictor MD Barboza, PhD student
victors.rb@gmail.com+ 55 11 997017706

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026